康莱特注射液改善老年晚期消化道肿瘤的临床症状分析  

KANGLAITE Injection ameliorated clinical symptoms of elderly patients with advanced gastrointestinal tract tumor

作　　者：姚淑莲[1] 成涛[1] 宁亚利[1] 李东辉[1] 李珉[1] 陈星[1] 刘清娥[1] 

机构地区：[1]陕西省人民医院老年肿瘤科,西安710068

出　　处：《肿瘤》2006年第4期387-388,共2页Tumor

摘　　要：目的:评价康莱特注射液改善老年晚期消化道肿瘤的临床疗效。方法:选择60岁以上的晚期消化道肿瘤患者,停止化疗2个月以上,将其随机分成2组,2组均采用营养支持加对症治疗,治疗组加用康莱特注射液静脉滴注,对照组不用康莱特注射液,比较2组KPS评分,体质量等变化差异。结果:KPS评分:治疗组改善加稳定率占78.85%,高于对照组52.08%,2组之间差异有统计学意义(P<0.05);体质量变化:治疗组体质量增加和稳定率占61.54%,明显高于对照组的35.42%,有统计学意义(P<0.05);近期疗效:虽然2组均未有达到CR+PR者,但治疗组病情稳定率占40.38%,高于对照组的20.83%,疾病进展治疗组占59.62%,低于对照组的79.17%,经统计学处理,有明显差异(P<0.05)。结论:老年晚期消化道肿瘤患者,已失去放、化疗机会或不能耐受放、化疗者,选用康莱特注射液能改善临床症状、提高生活质量、稳定疾病进展,而且临床应用安全,未见明显不良反应。Objective：To evaluate the clinical efficiency of KANGLAITA injection in the treatment of elderly patients with advanced gastrointestinal tract tumor. Methods：One hundred and four patients diagnosed as advanced gastrointestinal tract tumor were selected. They aged over 60 years and stopped chemotherapy for more than 2 months. The patients were randomly divided into two groups. The two groups both received nutrition support plus symptomatic treatment. The patients in KANGLAITA group were given additional intravenous injection of KANGLAITA simultaneously but the control group not. The Karnofsky performance status （KPS） score and weight change were compared between the two groups. Results：KPS score; 78.82% of patients experienced stable disease or better response in KANGLAITA group, which was significantly higher than that of control group（52.08%, P〈0.05 ）. Changes in weight： weight increases and stabilization occurred in 61.54% of patients in KANGLAITA group which was significantly higher than that of control group （35.52%, P〈0.05）. Short term efficacy; although no patients in the two group achieved complete response or partial response, no change was found in 40.38% of patients in KANGLAITA group and 20.83% of patients in control group [40. 38% of patients in KANGLAITA group and 20.83% of patients in control group had stable diseasez （P〈0.05）; progressive disease was observed in 59.62% of patients in KANGLAITA group and 79. 17% of patients in control group（P〈0.05）. Conclusion： KANGLAITA injection can ameliorate clinical symptom, increase life quality, and stabilize disease progression of elderly patients with advanced gastrointestinal tract tumor, who had lost the chance of chemotherapy and radiotherapy or could not tolerate them. KANGLAITA injection was relatively safe and had no apparent side effects in clinic.

关 键 词：中医药疗法 植物提取物 老年 晚期消化道肿瘤 康莱特注射液 

分 类 号：R273.5[医药卫生—中西医结合]